We use cookies for a better user experience. Read our Privacy Policy

I Agree

Osteogenesis Imperfecta Treatment Market

Osteogenesis Imperfecta Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Visceral Pain: Introduction

  • Osteogenesis imperfecta (OI) is a genetic disorder in which the bones fracture (break) easily. Sometimes, the fracture occurs for no known reason. OI can also lead to weak muscles, brittle teeth, a curved spine, and hearing loss. Symptoms of osteogenesis imperfecta can range from mild to severe; it may vary from person to person.
  • OI is caused by one of several genes that aren't working properly. When these genes don't work, they affect the production of collagen, a protein that makes the bones strong.
  • The four types of OI are: Osteogenesis Imperfecta Type I, Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III, and Osteogenesis Imperfecta Type IV. Of these, Osteogenesis type I is highly common and usually the mildest form of OI.

Key Drivers of Global Osteogenesis Imperfecta Treatment Market

  • Increase in number of patients with OI is likely to drive the market during the forecast period. According to National Organization for Rare Disorders, OI type I is estimated to occur in one in 30,000 live births. OI type II is estimated to occur in one in 60,000 live births. The overall prevalence of all types of OI is estimated at .5 per 10,000 individuals in the U.S. Approximately 20,000 to 50,000 individuals in the U.S. have OI.
  • Currently, available treatment options such as physical therapy, bracing, and medication (Bisphosphonates) do not treat the OI condition effectively. Therefore, several researchers are involved in research & development to develop novel therapies and treatment, which is expected to drive the global osteogenesis imperfecta treatment market.
  • Strong product pipeline for osteogenesis imperfecta is likely to boost the market during the forecast period. Currently, Amgen Inc. has one innovative drug product, i.e. Prolia, in phase III for the treatment of OI disease.

Teriparatide segment to expand significantly

  • In terms of drug class, the global osteogenesis imperfecta treatment market can be segregated into teriparatide, denosumab, and others
  • The teriparatide segment accounted for a significant share of the global osteogenesis imperfecta treatment market in 2019. Increase in use of teriparatide drugs in the treatment of OI is likely to propel the segment during the forecast period.

Oral to be highly lucrative segment

  • Based on route of administration, the global osteogenesis imperfecta treatment market can be classified into parenteral, oral, and others
  • The oral segment accounted for a significant share of the global market, in terms of revenue, in 2019. The trend is likely to continue during the forecast period. Most products can be administered through the oral route, which is likely to boost the segment.

Hospitals pharmacies to be highly promising segment

  • Based on distribution channel, the global osteogenesis imperfecta treatment market can be classified into hospital pharmacies, retail pharmacies, and online sales
  • The hospital pharmacies segment accounted for a prominent share of the market, in terms of revenue, in 2019. The segment is anticipated to expand during the forecast period as most major products are prescription products that are available at hospital pharmacies.

North America to Dominate Global Osteogenesis Imperfecta Treatment Market

  • In terms of region, the global osteogenesis imperfecta treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global osteogenesis imperfecta treatment market in 2019. The trend is projected to continue during the forecast period. The region’s dominance can be attributed to the presence of major market players and increase in focus on research and development activity in the region.
  • The osteogenesis imperfecta treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in adoption of new products and a rise in number of patients suffering from osteogenesis imperfecta.

Key Players Operating in Global Osteogenesis Imperfecta Treatment Market

The global osteogenesis imperfecta treatment market was highly fragmented in 2019. Key players operating in the global market are:

  • Bone Therapeutics SA
  • Mereo BioPharma Group plc
  • Celgene Corporation
  • Eli Lilly and Company
  • Cipla Inc.
  • Amgen Inc
  • Sun Pharmaceutical Industries Limited
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co., Inc.

Global Osteogenesis Imperfecta Treatment Market: Research Scope

  • Osteogenesis Imperfecta Treatment Market, by Drug Class
  • Teriparatide
  • Denosumab
  • Others

Global Osteogenesis Imperfecta Treatment Market, by Route of Administration

  • Oral
  • Parenteral
  • Others

Global Osteogenesis Imperfecta Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

Global Osteogenesis Imperfecta Treatment Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes

N/A

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

792

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved